Quick Answer
ORAMED PHARMACEUTICALS INC. reported Total Revenue of $2.00 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +49.3% in Total Revenue from 2023 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $125.0 thousand | Q2 2016: -$163.0 thousand | Q4 2016: $610.0 thousand | Q1 2017: $611.0 thousand | Q2 2017: $617.0 thousand | Q4 2017: $611.0 thousand | Q1 2018: $604.0 thousand | Q2 2018: $617.0 thousand | Q4 2018: $674.0 thousand | Q1 2019: $666.0 thousand | Q2 2019: $682.0 thousand | Q4 2019: $674.0 thousand | Q1 2020: $674.0 thousand | Q2 2020: $681.0 thousand | Q4 2020: $674.0 thousand | Q1 2021: $665.0 thousand | Q1 2021: $666.0 thousand | Q2 2021: $681.0 thousand | Q2 2021: $674.0 thousand | Q3 2021: $682.0 thousand | Q4 2021: $674.0 thousand | Q1 2022: $666.0 thousand | Q2 2022: $674.0 thousand | Q3 2022: $682.0 thousand | Q4 2022: $904.0 thousand | Q1 2023: $666.0 thousand | Q2 2023: $674.0 thousand | Q1 2025: $2.00 million.
- Over the full 9 years of available data (2016 to 2025), ORAMED PHARMACEUTICALS INC.'s Total Revenue has grown by 212.0%.
- Historical annual values: Fiscal year 2025: $2.00 million | Fiscal year 2023: $1.34 million | Fiscal year 2022: $2.70 million | Fiscal year 2021: $2.70 million | Fiscal year 2020: $2.71 million | Fiscal year 2019: $2.70 million | Fiscal year 2018: $2.45 million | Fiscal year 2017: $2.46 million | Fiscal year 2016: $641.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: